Crown Bioscience Forms Cancer Collaboration with Pfizer

Crown Bioscience, a pre-clinical CRO providing biology services for oncology indications, will collaborate with Pfizer to research and develop novel drugs for cancers that are prevalent in Asia and remain unaddressed medical needs. Crown will receive an upfront payment and research funding, as well as milestone payments upon achieving preclinical and clinical goals. The companies did not disclose specific financial details of their arrangement. More details... Stock Symbol: (NYSE: PFE)